These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 6346476

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical trial of a new antigonadotropic substance, 2,6-cis-diphenylhexamethylcyclotetrasiloxane, in cancer of the prostate. A pilot study.
    Collste L, Berlin T, von Garrelts B, Granberg I, Lewander R.
    Eur Urol; 1981; 7(2):85-8. PubMed ID: 7461008
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R, Nordle O, Josefsson K.
    J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
    [Abstract] [Full Text] [Related]

  • 6. Blood coagulation studies in patients with advanced carcinoma of the prostate treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane or estramustine-17-phosphate.
    Blombäck M, Edsmyr F, Kockum C, Paul C.
    Urol Res; 1978 May; 6(2):95-102. PubMed ID: 664137
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.
    Hedlund PO, Gustafson H, Sjögren S.
    Scand J Urol Nephrol Suppl; 1980 May; 55():103-5. PubMed ID: 6938012
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
    Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E, Scandinavian Prostatic Cancer Group.
    Scand J Urol Nephrol; 2002 May; 36(6):405-13. PubMed ID: 12623503
    [Abstract] [Full Text] [Related]

  • 12. Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study.
    Haapiainen R, Rannikko S, Alfthan O.
    Br J Urol; 1986 Oct; 58(5):528-33. PubMed ID: 3779355
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of prostatic carcinoma with various types of estrogen derivatives.
    Jönsson G, Olsson AM, Luttrop W, Cekan Z, Purvis K, Diczfalusy E.
    Vitam Horm; 1975 Oct; 33():351-76. PubMed ID: 1229063
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Clinical study of estramustine phosphate disodium (Estracyt) on prostatic cancer--results of long-term therapy for 38 patients with prostatic cancer].
    Asakawa M, Wada S, Hayahara N, Yayumoto R, Kishimoto T, Maekawa M, Morikawa Y, Kawakita J, Umeda M, Horii A.
    Hinyokika Kiyo; 1990 Nov; 36(11):1361-9. PubMed ID: 2288316
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.